France· FR:65395602
LYSAKARE 25 g/25 g, solution pour perfusion
A medicinal product containing chlorhydrate d'arginine + chlorhydrate de lysine, registered in France by NOVARTIS EUROPHARM (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE D'ARGININE + CHLORHYDRATE DE LYSINE
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550687471 poche PVC suremballée(s)/surpochée(s) de 1000 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chlorhydrate d'arginine + chlorhydrate de lysine in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomArginine 25g/1litre / Lysine 25g/1litre infusion bagsSpecial Order
- SpainLYSAKARE 25 G/25 G SOLUCION PARA PERFUSIONNovartis Europharm Limited
- FinlandLysakareNovartis Europharm Limited
- IrelandLysaKare 25 g/25 g Solution for infusionNovartis Europharm Limited
- IcelandLysaKareNovartis Europharm Limited*
- PolandLysaKareAdvanced Accelerator Applications
- CzechiaLYSAKARENovartis Europharm Limited, Dublin
- SwedenLysaKare 25 mg / 25 mg Infusionsvätska, lösningNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lysakare
- Liechtenstein · Lysakare
- Norway · Lysakare
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/39f604e4-61cc-4be3-aa35-92b39599ac78 GET /v1/drugs/39f604e4-61cc-4be3-aa35-92b39599ac78?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65395602",
"date_amm": "2019-07-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/19/1381",
"substance": "CHLORHYDRATE D'ARGININE + CHLORHYDRATE DE LYSINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about chlorhydrate d'arginine + chlorhydrate de lysine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.